A short, evidence-grounded conversation about NAD level and its place in longevity science.
Speaker 1
...and this is why human evidence is so crucial. We see a lot of excitement around NAD boosters, based on animal studies, but human trials often tell a more nuanced story.
Speaker 2
Exactly. Take NMN or NR, for example. They're precursors to NAD, which is vital for cellular energy and repair. In mice, supplementing these often shows incredible benefits, like improved metabolism or extended lifespan. But humans? It’s not always a direct translation.
Speaker 1
Right. A lot of the early human trials on NAD precursors focused on safety and pharmacokinetics, showing they do increase NAD levels. For instance, a 2023 study in Cell Metabolism showed NR supplementation increased NAD+ in blood cells. But what about the functional outcomes? Do these increased levels actually lead to measurable health benefits in healthy people?
Speaker 2
That's where it gets complicated. We're starting to see some promising, but small, studies. One in Nature Communications in 2027 indicated NR improved some metabolic markers in a specific population with insulin resistance. But for broader anti-aging claims in the general population, the evidence is still very limited. Many large, robust trials are still ongoing.
Speaker 1
And importantly, some trials show null results. Not every study finds a significant improvement in health or aging biomarkers, even when NAD levels go up. This doesn't mean it's useless, but it underscores that we still don't fully understand the optimal dosage, target populations, or long-term effects.
Speaker 2
Precisely. It’s a powerful example of why we need to separate the scientific potential from the current marketing hype, and really look at what the clinical trials, including those without dramatic findings, are telling us.
Educational research discussion only — not medical advice. Statements have not been
evaluated by the FDA. Nothing here is intended to diagnose, treat, cure or prevent any disease.
Talk to a qualified clinician before changing any treatment.